Due to health issues, this site is no longer maintained and will be shut down shortly. |
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. Living Cell Technologies Limited has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. The company was founded in 1987 and is based in Melbourne, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:LCT.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$0.06 OTCQB
As of 03/23/2023 OTCMarkets
2022 © Stock Market MBA, Inc.